Download Files:
Products Details
Product Description
– Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1].
Web ID
– HY-100399
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C27H39N3O
Citations
– Cell Rep. 2022 Nov 29;41(9):111724.|Structure. 2021 Sep 11;S0969-2126(21)00259-8.
References
– [1]LaPensee CR, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016 May;157(5):1775-88.
CAS Number
– 133825-80-6
Molecular Weight
– 421.62
SMILES
– O=C(NCC1(C2=CC=C(N(C)C)C=C2)CCCC1)NC3=C(C(C)C)C=CC=C3C(C)C
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Acyltransferase;Apoptosis
Isoform
– ACAT1;ACAT2
Pathway
– Apoptosis;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
